Skip to main content Skip to search Skip to main navigation

Swissmedic: Guidance on GMP-Compliance by Foreign Manufacturers and RP Declaration

The Swissmedic Guideline on GMP-Compliance by Foreign Manufacturers was published on 1.5.2023 as version 3.0. It is addressed to the holders of marketing authorisations for medicinal products from abroad or from Switzerland if these medicinal products contain active substances from foreign manufacturers.

The guideline clarifies which documents must be submitted with the marketing authorisation application or with the notification of a change to demonstrate that the GMP conformity check has been carried out by the responsible person (RP) in accordance with Art. 11 para. 1 part i Medicinal Products Licensing Ordinance (MPLO). For this purpose an existing GMP certificate which must not be older than three years and certifies GMP conformity equivalent to Switzerland may be sufficient or if applicable a corresponding audit report.

The following amendments have been introduced:

  • Chapter 5, which deals with verifying the conformity of foreign medicinal products and active substances, now contains a hierarchy of the documents to be submitted.
  • Chapter 6 on audit reports now specifies how, when and what information must be submitted to Swissmedic.
  • In Chapter 9 on inspections by Swissmedic, it has been added that an application can be put on hold until an inspection has taken place.

The guidelines and the new form for the declaration of the RP for foreign manufacturers can be found here.


Source:

Swissmedic: News and Updates

 

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

FDA: New Draft Guidance on Impurity Specifications for Antibiotics

FDA: New Draft Guidance on Impurity Specifications for Antibiotics

The US FDA has issued a new draft guidance (April 2026) on Impurity Specifications for Antibiotics.
Read more
EDQM: Guidance on Traceability of Medicines in Hospitals

EDQM: Guidance on Traceability of Medicines in Hospitals

The EDQM has published new guidance on the traceability of medicines in hospital settings. The aim is to improve traceability up to the point of administration and strengthen patient safety.
Read more
Which Measures are Crucial for Implementation and Monitoring of Data Integrity?

Which Measures are Crucial for Implementation and Monitoring of Data Integrity?

Here's the answer:
Read more
Contamination Control Strategy (CCS) – Not Just an Extended Site Master File

Contamination Control Strategy (CCS) – Not Just an Extended Site Master File

At the GMP-PharmaCongress in Wiesbaden, GMP inspector Frank Sielaff (Regional Authority in Darmstadt, Germany) shared practical insights from recent inspections, high-lighting deficiencies in CCS implementation.

Read more
EMA/HMA: Call for Regulatory Updates for Radiopharmaceuticals

EMA/HMA: Call for Regulatory Updates for Radiopharmaceuticals

In their „Horizon Scanning Report“, EMA and HMA have recommended updates to the regulatory framework to keep pace with developments in radiopharmaceuticals. Due to their unique characteristics these products require specific regulatory and scientific approaches.
Read more
How can the Specific Requirements for Sterile Products be Taken into Account in the Quality Management System?

How can the Specific Requirements for Sterile Products be Taken into Account in the Quality Management System?

Here's the answer:
Read more
Previous
Next